New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

Body:

Regeneron Pharmaceuticals, Inc. today announced that the New England Journal of Medicine (NEJM) published positive results from the Phase 3 trial of evinacumab in 65 patients with homozygous familial hypercholesterolemia (HoFH).

Category:

Front Page

Dates:

Monday, August 24, 2020 to Monday, November 16, 2020

Link the Feature to::

https://www.lipid.org/nla/new-england-journal-medicine-publishes-positive-phase-3-evinacumab-results-patients-severe

This page was last updated: Aug 24, 2020

To enhance the science and practice of lipidology and promote optimal cardiometabolic health.

new_about

new_practice

new_meetings

new_membership

new_communications

New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol

Search form

To enhance the science and practice of lipidology and promote optimal cardiometabolic health.

new_about

new_practice

new_meetings

new_membership

new_communications

New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol